GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » Shiller PE Ratio

Voyager Therapeutics (STU:VT6) Shiller PE Ratio : (As of Jun. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Voyager Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Voyager Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Shiller PE Ratio Chart

Voyager Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Voyager Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Voyager Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Voyager Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Shiller PE Ratio falls into.



Voyager Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Voyager Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Voyager Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.184/131.7762*131.7762
=-0.184

Current CPI (Mar. 2024) = 131.7762.

Voyager Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.000 100.560 0.000
201409 -0.233 100.428 -0.306
201412 -0.286 99.070 -0.380
201503 -0.993 99.621 -1.314
201506 -0.409 100.684 -0.535
201509 -0.239 100.392 -0.314
201512 -0.325 99.792 -0.429
201603 -0.260 100.470 -0.341
201606 -0.329 101.688 -0.426
201609 -0.312 101.861 -0.404
201612 -0.540 101.863 -0.699
201703 -0.608 102.862 -0.779
201706 -0.650 103.349 -0.829
201709 -0.747 104.136 -0.945
201712 -0.338 104.011 -0.428
201803 -0.511 105.290 -0.640
201806 -0.685 106.317 -0.849
201809 -0.540 106.507 -0.668
201812 -0.615 105.998 -0.765
201903 -0.717 107.251 -0.881
201906 0.257 108.070 0.313
201909 -0.372 108.329 -0.453
201912 -0.306 108.420 -0.372
202003 -0.597 108.902 -0.722
202006 -0.204 108.767 -0.247
202009 1.927 109.815 2.312
202012 -0.353 109.897 -0.423
202103 -0.487 111.754 -0.574
202106 -0.664 114.631 -0.763
202109 -0.570 115.734 -0.649
202112 0.133 117.630 0.149
202203 -0.508 121.301 -0.552
202206 -0.473 125.017 -0.499
202209 0.455 125.227 0.479
202212 -0.576 125.222 -0.606
202303 2.746 127.348 2.841
202306 -0.471 128.729 -0.482
202309 -0.553 129.860 -0.561
202312 1.091 129.419 1.111
202403 -0.184 131.776 -0.184

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Voyager Therapeutics  (STU:VT6) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Voyager Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyager Therapeutics (STU:VT6) Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (STU:VT6) Headlines

No Headlines